Skip to content

Francisco Madrid-Gambin

Applied Metabolomics Research Group, Hospital del Mar Research Institute, 08003 Barcelona, Spain. Electronic address: fmadrid@imim.es.

3 papers in the library · 16 citations · publishing 2023-2026

Papers

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics like LSD, mescaline, DMT, ayahuasca, 5-methoxy-DMT, and psilocybin induce altered states of consciousness and are being studied for treating mental health disorders. This review examines metabolic and metabolomics studies in humans after administration of these drugs. The main metabolites for classical psychedelics have been robustly established, but the metabolic alterations they induce need further exploration. Integrating metabolomics with pharmacokinetics may help understand the therapeutic role of psychedelics by revealing molecular interactions with multiple targets.

Metabolomic profiling of cannabis use and cannabis intoxication in humans.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May 1, 2025 Francisco Madrid-Gambin, Noemí Haro, Natasha L Mason et al. 4 citations

The metabolome—the collection of small molecules in blood—differs between occasional and chronic cannabis users both when sober and after acute THC intoxication. Fourteen metabolites, mainly involved in endocannabinoid and amino acid metabolism, distinguished the two groups with 80% accuracy. During intoxication, occasional users showed attentional impairment and elevated subjective high, accompanied by increases in organic acids, β-hydroxybutyrate, and ceramides; chronic users did not show these changes. The findings demonstrate that metabolomic profiling can identify metabolic alterations specific to the neurocognitive state of cannabis intoxication and to cannabis use frequency.

Brain-body integromics of the ayahuasca experience.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie June 1, 2026 Francisco Madrid-Gambin, Pablo Mallaroni, Noemí Haro et al.

The psychedelic state induced by ayahuasca arises from coordinated, system-level interactions between peripheral metabolism and brain network dynamics, rather than isolated neurochemical events. In 20 experienced ceremonial users, the subjective dimensions of oceanic boundlessness, visionary restructuralization, and auditory alterations covaried with circulating DMT and β-carbolines, shifts in lipid, amino acid, and energy metabolism, and reconfiguration of dorsal attention and default mode network connectivity. Shared features across these experiences were most strongly linked to endocannabinoid-related N-acylethanolamines, acylglycerols, and ceramides, extending beyond canonical serotonergic models to downstream lipid-signaling and metabolic processes. The findings offer translational insight into metabolic pathways that may modulate brain function and subjective response.